Biogen Inc
BIIB155.510USD
-1.230-0.78%
종가 11/07, 16:00（ET）시세는 15분 지연됩니다
22.81B시가총액
14.18P/E TTM
자세한 내용은 Biogen Inc 회사
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).
Biogen Inc 정보
종목 코드 BIIB
회사 이름Biogen Inc
상장일Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
직원 수7605
유형Ordinary Share
회계 연도 종료Sep 17
주소225 Binney Street
도시CAMBRIDGE
증권 거래소NASDAQ Global Select Consolidated
국가United States of America
우편 번호02142
전화17814642000
웹사이트https://www.biogen.com/
종목 코드 BIIB
상장일Sep 17, 1991
CEOMr. Christopher A. (Chris) Viehbacher
Biogen Inc의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
Mr. Jesus B. Mantas
Mr. Jesus B. Mantas
Independent Director
Independent Director
8.42K
+39.19%
Ms. Priya Singhal, M.D.
Ms. Priya Singhal, M.D.
Executive Vice President, Head of Development
Executive Vice President, Head of Development
5.77K
-8.22%
Dr. Maria C. Freire, Ph.D.
Dr. Maria C. Freire, Ph.D.
Independent Director
Independent Director
5.47K
+76.33%
Ms. Susan Langer
Ms. Susan Langer
Independent Director
Independent Director
3.79K
+166.90%
더 보기
이름
이름/직위
직위
주식 보유
변동
Ms. Susan H. Alexander, Esq., J.D.
Ms. Susan H. Alexander, Esq., J.D.
Executive Vice President, Chief Legal Officer
Executive Vice President, Chief Legal Officer
56.35K
+55.38%
Ms. Caroline D. Dorsa
Ms. Caroline D. Dorsa
Independent Chairman of the Board
Independent Chairman of the Board
29.22K
+12.13%
Dr. Ginger Gregory, Ph.D.
Dr. Ginger Gregory, Ph.D.
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
17.50K
+28.86%
Ms. Nicole Murphy
Ms. Nicole Murphy
Executive Vice President - Pharmaceutical Operations and Technology
Executive Vice President - Pharmaceutical Operations and Technology
14.22K
+1.19%
Dr. Stephen A. Sherwin, M.D.
Dr. Stephen A. Sherwin, M.D.
Independent Director
Independent Director
12.35K
+23.75%
Mr. Rachid Izzar
Mr. Rachid Izzar
Executive Vice President, Head of Global Product Strategy and Commercialization
Executive Vice President, Head of Global Product Strategy and Commercialization
11.23K
-16.53%
수익 분석
통화: USD마지막 업데이트: Mon, Oct 6
통화: USD마지막 업데이트: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
기타
498.00M
18.82%
지역별USD
이름
수익
비율
United States
1.38B
52.21%
Rest of World
937.60M
35.44%
United states-Revenues from anti-CD20 therapeutic
467.30M
17.66%
Rest of World-Other revenues
244.60M
9.25%
사업별
지역별
사업별USD
이름
수익
비율
MS product revenues-TYSABRI
839.80M
31.74%
Spinal Muscular Atrophy-SPINRAZA
543.00M
20.53%
MS product revenues-Fumarate
405.90M
15.34%
MS product revenues-Interferon
246.70M
9.33%
Biosimilar product revenues-BENEPALI
112.10M
4.24%
기타
498.00M
18.82%
주식 보유 통계
마지막 업데이트: Tue, Aug 19
마지막 업데이트: Tue, Aug 19
주주
주주 유형
주주
주주
비율
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.77%
BlackRock Institutional Trust Company, N.A.
5.58%
State Street Investment Management (US)
5.09%
Wellington Management Company, LLP
3.27%
기타
63.55%
주주
주주
비율
The Vanguard Group, Inc.
11.73%
PRIMECAP Management Company
10.77%
BlackRock Institutional Trust Company, N.A.
5.58%
State Street Investment Management (US)
5.09%
Wellington Management Company, LLP
3.27%
기타
63.55%
주주 유형
주주
비율
Investment Advisor
52.14%
Investment Advisor/Hedge Fund
24.35%
Hedge Fund
8.67%
Pension Fund
2.45%
Research Firm
2.27%
Sovereign Wealth Fund
1.59%
Bank and Trust
1.38%
Individual Investor
0.17%
Venture Capital
0.14%
기타
6.84%
기관 주식 보유
마지막 업데이트: Wed, Oct 1
마지막 업데이트: Wed, Oct 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q3
2020
136.90M
93.32%
-6.47M
2025Q2
2075
135.74M
92.58%
-12.69M
2025Q1
2149
136.82M
93.38%
-11.44M
2024Q4
2130
138.58M
94.69%
-5.19M
2024Q3
2109
135.95M
93.33%
-6.54M
2024Q2
2116
135.72M
93.21%
-7.14M
2024Q1
2121
136.44M
93.87%
-5.95M
2023Q4
2151
135.61M
93.59%
-2.07M
2023Q3
2177
132.42M
91.43%
-7.53M
2023Q2
2240
133.77M
92.42%
-4.86M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
17.21M
11.74%
+255.44K
+1.51%
Jun 30, 2025
PRIMECAP Management Company
15.80M
10.78%
-141.14K
-0.89%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.19M
5.59%
-504.36K
-5.80%
Jun 30, 2025
State Street Investment Management (US)
7.47M
5.09%
+71.90K
+0.97%
Jun 30, 2025
Wellington Management Company, LLP
4.80M
3.27%
+125.98K
+2.70%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.92M
2.67%
+71.29K
+1.85%
Jun 30, 2025
Point72 Asset Management, L.P.
3.83M
2.61%
+3.42M
+840.86%
Jun 30, 2025
Invesco Capital Management (QQQ Trust)
3.00M
2.05%
-10.62K
-0.35%
Aug 31, 2025
Norges Bank Investment Management (NBIM)
2.26M
1.54%
-61.02K
-2.62%
Jun 30, 2025
Invesco Capital Management LLC
2.04M
1.39%
+32.06K
+1.59%
Jun 30, 2025
더 보기
관련 ETF
마지막 업데이트: Thu, Nov 6
마지막 업데이트: Thu, Nov 6
이름
비율
Invesco Biotechnology & Genome ETF
5.03%
iShares Neuroscience and Healthcare ETF
4.13%
First Trust NASDAQ Pharmaceuticals ETF
3.82%
VanEck Biotech ETF
3.33%
First Trust NYSE Arca Biotechnology Index Fund
3.24%
Invesco Pharmaceuticals ETF
2.74%
First Trust Health Care Alphadex Fund
2.36%
Global X US Cash Flow Kings 100 ETF
2.26%
ProShares Ultra Nasdaq Biotechnology
2.12%
Invesco Nasdaq Biotechnology ETF
2.08%
더 보기
Invesco Biotechnology & Genome ETF
비율5.03%
iShares Neuroscience and Healthcare ETF
비율4.13%
First Trust NASDAQ Pharmaceuticals ETF
비율3.82%
VanEck Biotech ETF
비율3.33%
First Trust NYSE Arca Biotechnology Index Fund
비율3.24%
Invesco Pharmaceuticals ETF
비율2.74%
First Trust Health Care Alphadex Fund
비율2.36%
Global X US Cash Flow Kings 100 ETF
비율2.26%
ProShares Ultra Nasdaq Biotechnology
비율2.12%
Invesco Nasdaq Biotechnology ETF
비율2.08%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
